Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications.
Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.